ISRCTN64428072已完成Unknown
An adaptive, randomized, double-blind, placebo-controlled, single ascending dose (SAD) study to evaluate safety, pharmacokinetics (PK) and pharmacodynamics (PD) of GM-2505 in healthy volunteers
Gilgamesh Pharmaceuticals0 个研究点目标入组 48 人开始时间: 2024年7月4日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 发起方
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Healthy female or male subjects, aged 18 to 55 years old, inclusive. Healthy status is defined by absence of evidence of any active or chronic disease following a detailed medical, surgical a complete physical examination including vital signs, 12-lead ECG, hematology, blood chemistry, and urinalysis. If the results of the serum chemistry panel, hematology, or urinalysis are outside the normal reference ranges, the subject may be included only if the investigator judges the abnormalities to be not clinically significant.
- •2. Subject has a body mass index (BMI) between 18.0 and 30.0 kg/m2 inclusive (BMI=weight/height2) at screening.
- •3. Self-report of at least one prior hallucinogen drug experience that included a meaningful altered state of consciousness (a state in which the subject experienced phenomena that altered his psychological functioning, such as loss of ego boundaries, impaired control of actions and cognition, disembodiment, changed meaning of perception, visual alterations, and audio–visual synesthesia) in the past 5 years. Hallucinogenic substances can include psilocybin, LSD, DMT, ayahuasca, mescaline, ibogaine, 2C-drugs (such as 2CB, 2CI and 2CE) and/or ketamine.
- •4. Subjects must be willing to adhere to the prohibitions and restrictions specified in the protocol, including attending all study visits, preparatory and follow-up sessions, and completing all study evaluations.
- •5. Each subject must sign an informed consent form (ICF) indicating that he or she understands the purpose and procedures required for the study and are willing to participate in the study. Agree to refrain from using any psychoactive drugs from 30 days before first dosing and until the last follow-up visit and to refrain from using alcoholic beverages within 48 hours prior to admission of each treatment period.
排除标准
- •1. Clinically significant current or previous liver or renal insufficiency, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, metabolic or inflammatory illness, or any other illness that would compromise the well-being of the subject or the study or prevent the subject from meeting or performing study requirements according to the investigator.
- •3. Subject has a history of or current hypertension (resting systolic blood pressure > 130 mmHg or diastolic blood pressure >90 mmHg) at screening.
- •5. Resting heart rate (HR) greater than 100 or less than 45 beats per minute (bpm) at screening.
- •7. Clinically significant personal or familial history of epilepsy, seizures, convulsions, or other seizure disorder(excluding febrile seizures as a child), previous head trauma or other risk factor for seizure.
- •8. Clinically significant current or previous psychiatric disorder according to DSM 5. Specifically, current or previous psychotic disorders and bipolar disorder will be excluded.
- •9. Family history of a psychotic disorder (whether in the context of bipolar disorder, schizophrenia or schizoaffective disorder) in first-degree and second-degree relatives.
- •10. Clinically significant current or previous suicidality based on the C-SSRS and psychiatric history indicating current suicidal ideation or a history of active suicidal ideation or suicide attempts
- •11. Subject has a current or history of drug or alcohol use disorder according to the to DSM-IV and/or DSM 5within the past 12 months.
- •12. Use of psychoactive substances (including ketamine, esketamine, MDMA, cannabinoids), during the 6 weeks prior to screening. Single/occasional use may be allowed at the discretion of investigator.
- •13. Ingestion of psychedelics (including psilocybin, DMT/ayahuasca, LSD, another serotonergic psychedelic)during 4 weeks prior to screening.
- •14. Persistent psychological effects following the previous use of psilocybin, LSD, DMT, ayahuasca, mescaline, ibogaine, 2C-drugs (such as 2CB, 2CI and 2CE) and/or ketamine. Such effects might include but are not limited to anxiety, depressed mood, paranoid ideation and/or hallucinations (including hallucinogen persisting perception disorder – HPPD) or recurrent flashbacks related to use.
- •15. Subject has a positive test result(s) for alcohol and/or drugs of abuse (including opiates (including methadone),cocaine, amphetamines, methamphetamines, cannabinoids, barbiturates, and benzodiazepines) at screening or admission to the clinical unit.
研究者
相似试验
已完成
不适用
An adaptive, randomized, double-blind, placebo-controlled, single and multiple ascending dose study to examine the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of RGH-338 in healthy male volunteers.Autism spectrum disorderNL-OMON55280Gedeon Richter Plc.200
进行中（未招募）
1 期
A study on the safety and effects of the drug DMT in healthy smoking individualsReducing nicotine addiction in humansISRCTN11577984Entheon Biomedical Corp50
进行中（未招募）
1 期
A Study of the Safety and Efficacy of BLU-5937 for the Treatment of Chronic CoughRefractory Chronic CoughMedDRA version: 21.1Level: LLTClassification code 10066656Term: Chronic coughSystem Organ Class: 100000004855EUCTR2020-004136-17-HUBellus Health Inc.240
进行中（未招募）
1 期
A Study of the Safety and Efficacy of BLU-5937 for the Treatment of Chronic CoughEUCTR2020-004136-17-CZBellus Health Inc.240
进行中（未招募）
1 期
A Study of the Safety and Efficacy of BLU-5937 for the Treatment of Chronic CoughRefractory Chronic CoughMedDRA version: 21.1Level: LLTClassification code 10066656Term: Chronic coughSystem Organ Class: 100000004855EUCTR2020-004136-17-PLBellus Health Inc.240